Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by MBB Public Markets I LLC

MBB Public Markets I LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2,095.9% in the second quarter, HoldingsChannel reports. The fund owned 7,532 shares of the biopharmaceutical company’s stock after acquiring an additional 7,189 shares during the quarter. MBB Public Markets I LLC’s holdings in Regeneron Pharmaceuticals were worth $7,916,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of REGN. West Paces Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $26,000. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $1,039.96 on Friday. The firm’s 50 day moving average price is $1,129.87 and its 200 day moving average price is $1,033.99. The company has a market cap of $114.59 billion, a P/E ratio of 30.72, a PEG ratio of 3.72 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $8.79 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders sold 9,270 shares of company stock valued at $10,695,833 in the last ninety days. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Truist Financial restated a “buy” rating and issued a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada lowered their target price on shares of Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating on the stock in a research note on Tuesday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 16th. Finally, Barclays upped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,118.62.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.